ReviewCancer biology & therapy2009
The evolving role of mass spectrometry in cancer biomarker discovery.
Review in Cancer biology & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025Review
- CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials.Cancer metastasis reviews · 2024Review
- Cellular Therapy for Children with Central Nervous System Tumors: Mining and Mapping the Correlative Data.Current oncology reports · 2023Review
- On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances.International journal of molecular sciences · 2021Review
- Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.Nature reviews. Urology · 2021Review
- Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.Cell reports methods · 2021Article
- The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.Cell · 2021Review
- Clinical potential of mass spectrometry-based proteogenomics.Nature reviews. Clinical oncology · 2019Review
- Clinical biomarkers for cancer recognition and prevention: A novel approach with optical measurements.Cancer biomarkers : section A of Disease markers · 2018Review
- Targeted proteomic assays for quantitation of proteins identified by proteogenomic analysis of ovarian cancer.Scientific data · 2017Article
- Urinary biomarkers for renal tract malformations.Expert review of proteomics · 2016Review
- Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers.Clinical and translational medicine · 2016Review
- Network-Based Protein Biomarker Discovery Platforms.Genomics & informatics · 2016Review
- Emerging blood-based biomarkers for detection of gastric cancer.World journal of gastroenterology · 2015Review
- Discovery and targeted proteomics on cutaneous biopsies infected by borrelia to investigate lyme disease.Molecular & cellular proteomics : MCP · 2015Article
- Anti-peptide monoclonal antibodies generated for immuno-multiple reaction monitoring-mass spectrometry assays have a high probability of supporting Western blot and ELISA.Molecular & cellular proteomics : MCP · 2015Article
- Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers.Journal of proteome research · 2014Review
- Targeted proteomics: a bridge between discovery and validation.Expert review of proteomics · 2014Article
- Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.Molecular oncology · 2014Review
- Discovery of serum protein biomarkers in rheumatoid arthritis using MALDI-TOF-MS combined with magnetic beads.Clinical and experimental medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although the field of mass spectrometry-based proteomics is still in its infancy, recent developments in targeted proteomic techniques have left the field poised to impact the clinical protein biomarker pipeline now more than at any other time in history. for proteomics to meet its potential for finding biomarkers, clinicians, statisticians, epidemiologists and chemists must work together in an interdisciplinary approach. These interdisciplinary efforts will have the greatest chance for success if participants from each discipline have a basic working knowledge of the other disciplines. To that end, the purpose of this review is to provide a nontechnical overview of the emerging/evolving roles that mass spectrometry (especially targeted modes of mass spectrometry) can play in the biomarker pipeline, in hope of making the technology more accessible to the broader community for biomarker discovery efforts. Additionally, the technologies discussed are broadly applicable to proteomic studies, and are not restricted to biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.